Patrizia Genini

Ms. Patrizia Genini

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
FCFLORIANA DE CILLIS
FLORIANA DE CILLIS
VBVeronica Begni
Veronica Begni
PGPatrizia Genini
Patrizia Genini
DLDaniele Leo
Daniele Leo
Marco Andrea RivaMarco Andrea Riva
Marco Andrea Riva
ACAnnamaria Cattaneo
Annamaria Cattaneo
Major depressive disorder (MDD) is a complex, multifactorial condition involving dysregulation across immune, neural, and metabolic systems. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have emerged as promising adjunctive interventions, with evidence supporting their efficacy in alleviating depressive symptoms. Here, we synthesize current knowledge on the interconnected biological pathways through which n-3 PUFAs may exert antidepressant effects. A growing body of evidence implicates the gut–brain axis as a central pathway through which n-3 PUFAs may exert antidepressant effects. By shaping microbiota composition and metabolite production, n-3 PUFAs influence intestinal permeability, immune activation, and vagal signaling, thereby contributing to both immunomodulatory and neurochemical effects. In combination, n-3 PUFAs modulate peripheral and central inflammation by promoting specialized pro-resolving mediators, downregulating pro-inflammatory cytokines, and influencing microglial activation. Parallel actions on neuronal membrane composition and lipid raft integrity affect neurotransmitter signaling, synaptic plasticity, and neurogenesis, with downstream effects on neural function. Additional pathways, including hypothalamic–pituitary–adrenal axis regulation and oxidative stress reduction, further integrate n-3 PUFA actions across multiple systems. Collectively, these mechanisms suggest that n-3 PUFAs act as network modulators, supporting recovery in depression. Translational research highlights the importance of EPA-predominant formulations, optimal dosing, and patient stratification. By framing n-3 PUFAs activity within a multi-level systems biology perspective, this review provides a comprehensive mechanistic understanding and underscores their potential as targeted adjunctive strategies for MDD.

29 March 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
MBMaria Grazia Di Benedetto
Maria Grazia Di Benedetto
KPKristi M. S. Priestley
Kristi M. S. Priestley
NCNadia Cattane
Nadia Cattane
PGPatrizia Genini
Patrizia Genini
SSSamantha Saleri
Samantha Saleri
ACAnnamaria Cattaneo
Annamaria Cattaneo
During pregnancy multiple biological systems undergo consistent modifications, in particular the hormonal axes and the immune system. Moreover, while it is well known that pregnant women suffering from depression show alterations in these systems, the exact underlying mechanisms are still not clear. For this reason, in this study, we explored the blood transcriptomic profile and related pathways in 41 pregnant women with a current diagnosis of depression, 23 pregnant women, who were not depressed in pregnancy but, because of a history of depressive episodes, were considered at high risk of developing antenatal depression (history-only), and 28 pregnant women who had never experienced depression in their life, including the current pregnancy. Based on resulting differentially expressed genes, we identified 28 molecular pathways modulated in depressed women compared with controls, with a main association with increased B cell activity, while history-only women showed 52 pathways differentially modulated compared with controls, involving lower cytotoxic T cell activity and higher pro-inflammatory pathways activity. Conversely, depressed women showed a differential modulation of 75 pathways, compared with history-only women, associated with increased activity of allo- and auto-immunity and pro-inflammatory pathways. Overall, our results suggest a main role of immunity within the context of perinatal depression, and of a differential modulation of specific immune processes underlying the development of depression and the associated risk.

22 November 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
PGPatrizia Genini
Patrizia Genini
IDIlari D’Aprile
Ilari D’Aprile
GPGiulia Petrillo
Giulia Petrillo
MBMaria Grazia Di Benedetto
Maria Grazia Di Benedetto
VBVeronica Begni
Veronica Begni
ACAnnamaria Cattaneo
Annamaria Cattaneo
Depression is a leading cause of global disability and is increasingly recognized as a multifactorial disorder characterized by fundamental disruptions in neuroplasticity, including diminished hippocampal neurogenesis, impaired synaptic plasticity, and dysregulated stress-response systems. Given the limited efficacy of conventional pharmacological treatments, lifestyle-based interventions—most notably physical exercise—have gained considerable attention for their antidepressant effects, partly mediated by secreted exerkines. Among these, adiponectin has emerged as a particularly compelling candidate linking metabolic regulation to neuroplasticity and mood. Recent evidence suggests that adiponectin contributes to the antidepressant effects of exercise by modulating hippocampal neurogenesis, neuroinflammation, and brain-derived neurotrophic factor (BDNF) signalling. Despite these advances, the mechanisms by which adiponectin influences depression remain incompletely understood. This review synthesizes current knowledge on adiponectin’s role in depression pathophysiology, with emphasis on its capacity to enhance neuroplasticity and hippocampal neurogenesis, and its potential to mediate exercise-induced antidepressant effects via defined molecular pathways. Building on these insights, we discuss adiponectin’s translational promise as both a predictive biomarker of treatment response and a novel therapeutic target. By integrating preclinical and clinical evidence, this review offers a comprehensive perspective on adiponectin’s involvement in depression while identifying critical gaps to guide future mechanistic research.

3 January 2026 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
GPGiulia Poggi
Giulia Poggi
GTGiulia Treccani
Giulia Treccani
PGPatrizia Genini
Patrizia Genini
MPMarta Da Pian
Marta Da Pian
ACAnnamaria Cattaneo
Annamaria Cattaneo
NCNadia Cattane
Nadia Cattane
Background Stressful life events (SLE) are associated with an increased likelihood of developing depression. However, the underlying mechanisms and the long-lasting consequences of SLE exposure during adolescence, a critical period for physical, sexual, and behavioural maturation, are largely unknown. Recent studies suggest that they might be mediated by aberrant epigenetic mechanisms, such as alterations in DNA methylation, histone modifications and the expression of microRNAs. This systematic review aims at investigating the epigenetic markers affected by SLE during adolescence and their (causal) contribution to the onset of depression later in life. Methods In line with the PRISMA 2020 guidelines and following a pre-registered protocol (CRD42023441784), PubMed, Web of Science and Embase were screened and 30 studies, including both rodents (n = 19) and humans (n = 11), met the pre-defined inclusion criteria. Results The preclinical findings converge on SLE-related changes in DNA methylation of Bdnf gene and alterations in microRNAs implicated in the regulation of Bdnf- and glucocorticoid-related pathways. The clinical studies focused primarily on DNA methylation and microRNAs alterations. Whilst a consensus on specific SLE-related epigenetic modifications did not emerge, novel pathways, including extracellular vesicle (EV) miRNAs, should be further investigated to be employed as biomarkers for preventive screening. Discussion Overall, our systematic review provides early suggestive evidence on the role of epigenetic mechanisms in mediating the effects of SLE in adolescence and the consequent onset of depression-relevant symptoms in later life. However, the paucity and the heterogeneity of the findings highlight the need for additional studies to address this fundamental research question and provide solid evidence for causality.

3 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PGPatrizia Genini
Patrizia Genini
IDIlari D’Aprile
Ilari D’Aprile
GPGiulia Petrillo
Giulia Petrillo
MBMaria Grazia Di Benedetto
Maria Grazia Di Benedetto
VBVeronica Begni
Veronica Begni
ACAnnamaria Cattaneo
Annamaria Cattaneo
Depression is a leading cause of global disability and is increasingly recognized as a multifactorial disorder characterized by fundamental disruptions in neuroplasticity, including diminished hippocampal neurogenesis, impaired synaptic plasticity, and dysregulated stress-response systems. Given the limited efficacy of conventional pharmacological treatments, lifestyle-based interventions—most notably physical exercise—have gained considerable attention for their antidepressant effects, partly mediated by secreted exerkines. Among these, adiponectin has emerged as a particularly compelling candidate linking metabolic regulation to neuroplasticity and mood. Recent evidence suggests that adiponectin contributes to the antidepressant effects of exercise by modulating hippocampal neurogenesis, neuroinflammation, and brain-derived neurotrophic factor (BDNF) signalling. Despite these advances, the mechanisms by which adiponectin influences depression remain incompletely understood. This review synthesizes current knowledge on adiponectin’s role in depression pathophysiology, with emphasis on its capacity to enhance neuroplasticity and hippocampal neurogenesis, and its potential to mediate exercise-induced antidepressant effects via defined molecular pathways. Building on these insights, we discuss adiponectin’s translational promise as both a predictive biomarker of treatment response and a novel therapeutic target. By integrating preclinical and clinical evidence, this review offers a comprehensive perspective on adiponectin’s involvement in depression while identifying critical gaps to guide future mechanistic research.